Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent before any study related procedure~* Male and female patients age 18 years or older at time of enrollment~* Diagnosis of intestinal obstruction of malignant origin~* In case of peritoneal carcinomatosis, confirmation by CT or MRI scan within the 3 months preceding the inclusion in the study~* Confirmed as inoperable after surgical advice~* Patient with a nasogastric tube OR presenting with 3 or more episodes of vomiting / 24h in the last 48 hours~* Estimated life expectancy 1 month or more~Exclusion Criteria:~* Operable obstruction or subobstruction~* Bowel obstruction due to a non-malignant cause~* Signs of bowel perforation~* Prior treatment with somatostatin or any other analogue within the previous 60 days~* A known hypersensitivity to any of the study treatments or related compounds~* Previous participation in this study~* Is likely to require treatment during the study with drugs that are not permitted by the study protocol~* Has abnormal baseline findings, any other medical condition(s) or laboratory findings that, in the opinion of the Investigator, might jeopardise the subject's safety

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lanreotide Autogel (Type: EXPERIMENTAL): 120mg administered via deep subcutaneous injection at Day 0 and Day 28.

Based on this trial design, predict the completion outcome and termination type (if applicable).